RxDoctor Payments Data

George Moskowitz, MD

Family Medicine · Brooklyn, NYNPI 1164417945

Payments from drug & device makers

$805in general payments, 2019–2025

Across 31 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$159
  • Boehringer Ingelheim$125
  • Johnson & Johnson$124
  • Endo Pharmaceuticals Inc.$108
  • Pfizer$76
  • Exact Sciences$67
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$301,020
Medicare patients
159
Services billed
9,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$58,993
TrulicityDulaglutide48$43,230
SpravatoEsketamine Hcl25$27,695
JardianceEmpagliflozin32$27,436
JanuviaSitagliptin Phosphate39$25,789
OzempicSemaglutide24$21,988
MounjaroTirzepatide19$19,664
CreonLipase/Protease/Amylase12$9,156
BrilintaTicagrelor23$7,461
VascepaIcosapent Ethyl14$4,847
Incruse ElliptaUmeclidinium Bromide12$3,758
Diclofenac Sodium ErDiclofenac Sodium36$3,017
Dexlansoprazole DrDexlansoprazole16$2,851
Metoprolol Succinate130$1,648
Albuterol Sulfate HfaAlbuterol Sulfate39$1,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$58,99378 claims
Johnson & JohnsonSpravato$124$27,69525 claims
Boehringer IngelheimJardiance$125$27,43632 claims
MerckJanuvia$16$25,78939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →